Big gain for ORIC in trading debut after pricing upsized IPO

By posting a big gain Friday after pricing an upsized IPO at the top end of its range, ORIC provided another encouraging data point to biotechs seeking to test the public markets, suggesting that investors continue to have an appetite for new listings.

Late Thursday, ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) priced 7.5 million shares at $16, raising $120 million at a postmoney valuation of $460.7 million. The stock finished its first day of trading up $9.77 (61%) to $25.77...